It was announced today that Edwards Lifesciences Corporation plans to increase its investment in Ireland by more than €80 million with the construction of a new and larger medical technology plant in the Mid-West of Ireland. This takes Edwards’ initial investment in the project of €80 million to more than €160 million.
Edwards Lifesciences Corporation provides patient-focused innovations for structural heart disease and critical care monitoring and is headquartered in Irvine, California, USA.
Edwards plans to open the new purpose-built facility in Castletroy, Limerick City, in 2021 and, once fully operational, it is expected to employ approximately 600 people, as previously announced. The state-of-the-art facility will focus on manufacturing sophisticated medical technologies, such as delivery systems and other components for Edwards’ market-leading therapies for structural heart disease.
Edwards established operations in Ireland in 2018, and employs 50 people at a facility in the Shannon Freezone. The additional investment around its new facility includes the purchase of additional land, the construction of a larger facility to allow for possible future expansion and the integration of upgraded technology.
Speaking today, Taoiseach Leo Varadkar said, "The development of the Limerick city region is a major part of Project Ireland 2040. We are planning for the city to grow by 50 percent over the next two decades through enhanced regional accessibility, improved international connectivity and a competitive, educated workforce."
He added, "The fact that Edwards Lifesciences has chosen Limerick for this new permanent facility is a very positive endorsement of the region as a great place in which to live, work and invest. Lifesaving, cutting-edge technologies will be produced here, resulting in the creation of 600 highly skilled jobs. I wish the company and their new workforce the very best as they embark on this exciting new project."